OSE Immunotherapeutics SA(FR:OSE)
€1.73+0.03 (+1.82%)
FR:OSE
OSE Immunotherapeutics SA stock drug pipeline
€1.73
At close:+0.03 (+1.82%)
Want to see FR:OSE full AI Analyst Report?
OSE Immunotherapeutics SA (OSE) Drug Pipeline
18 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does OSE Immunotherapeutics (FR:OSE) have in its pipeline
OSE Immunotherapeutics SA FR:OSE is currently developing the following drugs: Docetaxel, Ose2101, Ngs Hlaa2 Assay, Ose-279 100Mg, Ose-279 300Mg, Ose-279 500Mg, Covepit (Ose13e), Ose-127, Bi 765063, Bi 754091, Fr104, Docetaxel, Pemetrexed, Ose2101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

